With the availability of over a dozen disease-modifying therapies (DMTs) to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market has accommodated a place for each therapy due to a heterogeneous disease, individualized treatment decisions, and a mix of positive and negative attributes that defines each DMT. With every new launch, players in the MS space—both new and old—must assess where their products fit into an increasingly crowded market. Meanwhile, competing paradigms of escalation vs. early intervention with high-efficacy drugs remain a source of debate. As such, patients’ journey through lines of therapy will continue to evolve. National patient-level claims data explores the current DMTs’ position in newly diagnosed and recently treated patients, examines line of therapy progression including treatment duration and switch patterns, and persistence and compliance by brand.
- What patient share do key brands garner by line of therapy in newly diagnosed MSpatients? What are the quarterly trends in prescribing among recently treated and new diagnosed MS patients?
- How have newer entrants been integrated into the treatment algorithm?
- What proportion of MS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What are the product-level compliance and persistency rates among drug-treated patients with MS?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.